Zobrazeno 1 - 10
of 2 260
pro vyhledávání: '"Semagacestat"'
Autor:
Shinji Tagami, Kanta Yanagida, Takashi S. Kodama, Mako Takami, Naoki Mizuta, Hiroshi Oyama, Kouhei Nishitomi, Yu-wen Chiu, Toru Okamoto, Takeshi Ikeuchi, Gaku Sakaguchi, Takashi Kudo, Yoshiharu Matsuura, Akio Fukumori, Masatoshi Takeda, Yasuo Ihara, Masayasu Okochi
Publikováno v:
Cell Reports, Vol 21, Iss 1, Pp 259-273 (2017)
γ-secretase inhibitors (GSI) are drugs developed to decrease amyloid-β peptide (Aβ) production by inhibiting intramembranous cleavage of β-amyloid protein precursor (βAPP). However, a large phase 3 trial of semagacestat, a potential non-transiti
Externí odkaz:
https://doaj.org/article/e0c2b7842afc48ba9915c840c0c2dbd5
Autor:
Tagami, Shinji, Yanagida, Kanta, Kodama, Takashi S., Takami, Mako, Mizuta, Naoki, Oyama, Hiroshi, Nishitomi, Kouhei, Chiu, Yu-wen, Okamoto, Toru, Ikeuchi, Takeshi, Sakaguchi, Gaku, Kudo, Takashi, Matsuura, Yoshiharu, Fukumori, Akio, Takeda, Masatoshi, Ihara, Yasuo, Okochi, Masayasu
Publikováno v:
In Cell Reports 3 October 2017 21(1):259-273
Autor:
Doody, Rachelle S.1, Raman, Rema2,3, Sperling, Reisa A.4, Seimers, Eric5, Sethuraman, Gopalan5, Mohs, Richard5, Farlow, Martin6, Takeshi Iwatsubo7, Vellas, Bruno8, Xiaoying Sun9, Ernstrom, Karin9, Thomas, Ronald G.3,10, Aisen, Paul S.3 paisen@ucsd.edu
Publikováno v:
Alzheimer's Research & Therapy. 2015, Vol. 7 Issue 1, p1-7. 7p.
Autor:
Hölttä, Mikko1, Dean, Robert A.2, Siemers, Eric2, Mawuenyega, Kwasi G.3, Sigurdson, Wendy3,4, May, Patrick C.2, Holtzman, David M.3,4,5, Portelius, Erik1, Zetterberg, Henrik1,6, Bateman, Randall J.3,4,5, Blennow, Kaj1, Gobom, Johan1 johan.gobom@neuro.gu.se
Publikováno v:
Alzheimer's Research & Therapy. 3/7/2016, Vol. 8, p1-8. 8p.
Autor:
Carlson, Christopher, Estergard, Wahiba, Oh, Joonmi, Suhy, Joyce, Jack, Clifford R., Jr., Siemers, Eric, Barakos, Jerome
Publikováno v:
In Alzheimer's & Dementia: The Journal of the Alzheimer's Association 2011 7(4):396-401
Semagacestat, a γ-secretase inhibitor, demonstrated an unfavorable risk–benefit profile in a Phase 3 study of patients with Alzheimer’s disease (IDENTITY trials), and clinical development was halted. To assist in future development of γ-secreta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::617aab97728530126cae39ab06d46174
Autor:
Masatoshi Takeda, Shinji Tagami, Yasuo Ihara, Takeshi Ikeuchi, Akio Fukumori, Hiroshi Oyama, Masayasu Okochi, Kanta Yanagida, Yu-wen Chiu, Takashi S. Kodama, Toru Okamoto, Mako Takami, Naoki Mizuta, Takashi Kudo, Kouhei Nishitomi, Yoshiharu Matsuura, Gaku Sakaguchi
Publikováno v:
Cell Reports, Vol 21, Iss 1, Pp 259-273 (2017)
Summary γ-secretase inhibitors (GSI) are drugs developed to decrease amyloid-β peptide (Aβ) production by inhibiting intramembranous cleavage of β-amyloid protein precursor (βAPP). However, a large phase 3 trial of semagacestat, a potential non-
Autor:
Xiaoying Sun, Rema Raman, Anton P. Porsteinsson, Paul B. Rosenberg, Krista L. Lanctôt, Nathan Herrmann, Jacobo Mintzer
Publikováno v:
Journal of Alzheimer's Disease. 54:373-381
Background In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD). Objective We sought to examine the effect of semagacestat treatment on neuro
Publikováno v:
Frontiers in Aging Neuroscience, Vol 16 (2024)
BackgroundNow, there are no sensitive biomarkers for improving Alzheimer’s disease (AD) and comorbid Parkinson’s disease (PD). The aim of the present study was to analyze differentially expressed genes (DEGs) in brain tissue from AD and PD patien
Externí odkaz:
https://doaj.org/article/81353f4e23474e77ba03598f3f5f9c48
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.